Literature DB >> 22983985

Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family.

Masanobu Takahashi1, Bokyung Sung, Yan Shen, Keun Hur, Alexander Link, C Richard Boland, Bharat B Aggarwal, Ajay Goel.   

Abstract

Colorectal cancer (CRC) is a complex disease with genetic and epigenetic alterations in many key oncogenes and tumor suppressor genes. The active principle of a gum resin from Boswellia serrata, 3-acetyl-11-keto-β-boswellic acid (AKBA), has recently gained attention as a chemopreventive compound due to its ability to target key oncogenic proteins such as 5-lipoxygenase and nuclear factor-kappaB. AKBA has been shown to inhibit the growth of CRC cells; however, the precise molecular mechanisms underlying its anticancer activities in CRC remain unclear. We hypothesized that boswellic acids may achieve their chemopreventive effects by modulating specific microRNA (miRNA) pathways. We found that AKBA significantly up-regulated expression of the let-7 and miR-200 families in various CRC cell lines. Both let-7 and miR-200 are putative tumor-suppressive miRNAs. AKBA modulated the expression of several downstream targets of the let-7 and miR-200 families, such as CDK6, vimentin and E-cadherin. These data were further strengthened by miRNA knockdown studies, which revealed that inhibition of let-7i facilitated enhanced cancer cell proliferation, migration and invasion. In addition, AKBA also induced similar modulation of the let-7 and miR-200 downstream genes in CRC tumors orthotopically implanted in nude mice. These results indicate that AKBA-induced antitumor effects in CRC occur, at least partly through the up-regulation of specific miRNA pathways. Our data provide novel evidence that anticancer effects of boswellic acids are due in part to their ability to regulate cellular epigenetic machinery and further highlight the promise for this phytochemical in the preventative and therapeutic applications of CRC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22983985      PMCID: PMC3510738          DOI: 10.1093/carcin/bgs286

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  45 in total

1.  A combined computational-experimental approach predicts human microRNA targets.

Authors:  Marianthi Kiriakidou; Peter T Nelson; Andrei Kouranov; Petko Fitziev; Costas Bouyioukos; Zissimos Mourelatos; Artemis Hatzigeorgiou
Journal:  Genes Dev       Date:  2004-05-06       Impact factor: 11.361

2.  MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.

Authors:  Masanobu Takahashi; Minoru Koi; Francesc Balaguer; C Richard Boland; Ajay Goel
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

3.  Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers.

Authors:  Vivek R Yadav; Sahdeo Prasad; Bokyung Sung; Juri G Gelovani; Sushovan Guha; Sunil Krishnan; Bharat B Aggarwal
Journal:  Int J Cancer       Date:  2011-09-12       Impact factor: 7.396

4.  EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells.

Authors:  Carmen S Tellez; Daniel E Juri; Kieu Do; Amanda M Bernauer; Cindy L Thomas; Leah A Damiani; Mathewos Tessema; Shuguang Leng; Steven A Belinsky
Journal:  Cancer Res       Date:  2011-03-01       Impact factor: 12.701

Review 5.  Targeting microRNAs in cancer: rationale, strategies and challenges.

Authors:  Ramiro Garzon; Guido Marcucci; Carlo M Croce
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

Review 6.  Pancreatic cancer: understanding and overcoming chemoresistance.

Authors:  Zhiwei Wang; Yiwei Li; Aamir Ahmad; Sanjeev Banerjee; Asfar S Azmi; Dejuan Kong; Fazlul H Sarkar
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-23       Impact factor: 46.802

7.  Cytostatic and apoptosis-inducing activity of boswellic acids toward malignant cell lines in vitro.

Authors:  Katarina Hostanska; Gerhard Daum; Reinhard Saller
Journal:  Anticancer Res       Date:  2002 Sep-Oct       Impact factor: 2.480

8.  Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells.

Authors:  Jian-Jun Liu; Ake Nilsson; Stina Oredsson; Vladimir Badmaev; Wan-Zhou Zhao; Rui-Dong Duan
Journal:  Carcinogenesis       Date:  2002-12       Impact factor: 4.944

9.  LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms.

Authors:  C E King; L Wang; R Winograd; B B Madison; P S Mongroo; C N Johnstone; A K Rustgi
Journal:  Oncogene       Date:  2011-05-30       Impact factor: 9.867

10.  Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis.

Authors:  V Davalos; C Moutinho; A Villanueva; R Boque; P Silva; F Carneiro; M Esteller
Journal:  Oncogene       Date:  2011-08-29       Impact factor: 9.867

View more
  30 in total

1.  Triterpenoid resinous metabolites from the genus Boswellia: pharmacological activities and potential species-identifying properties.

Authors:  Yuxin Zhang; Zhangchi Ning; Cheng Lu; Siyu Zhao; Jianfen Wang; Baoqin Liu; Xuegong Xu; Yuanyan Liu
Journal:  Chem Cent J       Date:  2013-09-12       Impact factor: 4.215

2.  Identification of a metastasis-specific MicroRNA signature in human colorectal cancer.

Authors:  Keun Hur; Yuji Toiyama; Aaron J Schetter; Yoshinaga Okugawa; Curtis C Harris; C Richard Boland; Ajay Goel
Journal:  J Natl Cancer Inst       Date:  2015-02-06       Impact factor: 13.506

3.  Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.

Authors:  Kazuhiro Yoshida; Shusuke Toden; Preethi Ravindranathan; Haiyong Han; Ajay Goel
Journal:  Carcinogenesis       Date:  2017-10-01       Impact factor: 4.944

4.  Novel Evidence for Curcumin and Boswellic Acid-Induced Chemoprevention through Regulation of miR-34a and miR-27a in Colorectal Cancer.

Authors:  Shusuke Toden; Yoshinaga Okugawa; Constanze Buhrmann; Durgha Nattamai; Esperanza Anguiano; Nicole Baldwin; Mehdi Shakibaei; C Richard Boland; Ajay Goel
Journal:  Cancer Prev Res (Phila)       Date:  2015-02-23

5.  Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer.

Authors:  Shusuke Toden; Yoshinaga Okugawa; Thomas Jascur; Dominik Wodarz; Natalia L Komarova; Constanze Buhrmann; Mehdi Shakibaei; C Richard Boland; Ajay Goel
Journal:  Carcinogenesis       Date:  2015-02-04       Impact factor: 4.944

6.  Current Perspectives on Epigenetic Modifications by Dietary Chemopreventive and Herbal Phytochemicals.

Authors:  Yue Guo; Zheng-Yuan Su; Ah-Ng Tony Kong
Journal:  Curr Pharmacol Rep       Date:  2015-08

Review 7.  Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers.

Authors:  Anne Yuqing Yang; Hyuck Kim; Wenji Li; Ah-Ng Tony Kong
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

8.  Dysregulation of microRNA-34a expression in colorectal cancer inhibits the phosphorylation of FAK via VEGF.

Authors:  Danhua Zhang; Jianping Zhou; Ming Dong
Journal:  Dig Dis Sci       Date:  2013-12-27       Impact factor: 3.199

Review 9.  Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds.

Authors:  Abedul Haque; Daniel Brazeau; Arm R Amin
Journal:  Eur J Cancer       Date:  2021-04-14       Impact factor: 9.162

Review 10.  Novel Genetic and Epigenetic Biomarkers of Prognostic and Predictive Significance in Stage II/III Colorectal Cancer.

Authors:  Xiao-Jing Luo; Qi Zhao; Jia Liu; Jia-Bo Zheng; Miao-Zhen Qiu; Huai-Qiang Ju; Rui-Hua Xu
Journal:  Mol Ther       Date:  2020-12-15       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.